Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 22;25(18):10169.
doi: 10.3390/ijms251810169.

The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature

Anna Kucharska  1 , Ewelina Witkowska-Sędek  1 , Michał Erazmus  1 , Dorota Artemniak-Wojtowicz  1 , Maria Krajewska  1 , Beata Pyrżak  1
Affiliations

The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature

Anna Kucharska et al. Int J Mol Sci. .

Abstract

Recombinant human growth hormone therapy (rhGH) has been widely accepted as the safe treatment for short stature in children with such genetic syndromes as Prader-Willi syndrome and Turner or Noonan syndrome. Some patients with short stature and rare genetic syndromes are treated with rhGH as growth hormone-deficient individuals or as children born small for their gestational age. After years of experience with this therapy in syndromic short stature, it has been proved that there are some aspects of long-term rhGH treatment beyond growth promotion, which can justify rhGH use in these individuals. This paper summarizes the data of a literature review of the effects of rhGH treatment beyond growth promotion in selected genetic syndromes. We chose three of the most common syndromes, Prader-Willi, Turner, and Noonan, in which rhGH treatment is indicated, and three rarer syndromes, Silver-Russel, Kabuki, and Duchenne muscular dystrophy, in which rhGH treatment is not widely indicated. Many studies have shown a significant impact of rhGH therapy on body composition, resting energy expenditure, insulin sensitivity, muscle tonus, motor function, and mental and behavioral development. Growth promotion is undoubtedly the primary benefit of rhGH therapy; nevertheless, especially with genetic syndromes, the additional effects should also be considered as important indications for this treatment.

Keywords: QoL; bone; children; genetic syndromes; growth hormone treatment; metabolic effects; muscle.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA 2020 flow diagram systematic reviews of rhGH therapy effects in children with selected genetic syndromes. PWS—Prader–Willi syndrome; TS—Turner syndrome; NS—Noonan syndrome; SRS—Silver–Russel syndrome; KS—Kabuki syndrome; DMD—Duchenne muscular dystrophy, rhGH—recombinant human growth hormone.
Figure 2
Figure 2
Comparison between percentage of papers regarding rhGH effects beyond growth promotion among PWS (% of 83 papers), TS (% of 51 papers), and NS (% of 26 papers). PWS—Prader–Willi syndrome; TS—Turner syndrome; NS—Noonan syndrome.
See this image and copyright information in PMC

References

    1. Cassidy S.B., Schwartz S., Miller J.L., Driscoll D.J. Prader-Willi syndrome. Genet. Med. 2012;14:10–26. doi: 10.1038/gim.0b013e31822bead0. - DOI - PubMed
    1. Kimonis V.E., Tamura R., Gold J.A., Patel N., Surampalli A., Manazir J., Miller J.L., Roof E., Dykens E., Butler M.G., et al. Early diagnosis in Prader-Willi syndrome reduces obesity and associated co-morbidities. Genes. 2019;10:898. doi: 10.3390/genes10110898. - DOI - PMC - PubMed
    1. Deal C.L., Tony M., Höybye C., Allen D.B., Tauber M., Christiansen J.S., 2011 Growth Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop Participants Growth Hormone Research Society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2013;98:E1072–E1087. doi: 10.1210/jc.2012-3888. - DOI - PMC - PubMed
    1. Gravholt C.H., Andersen N.H., Conway G.S., Dekkers O.M., Geffner M.E., Klein K.O., Lin A.E., Mauras N., Quigley C.A., Rubin K., et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur. J. Endocrinol. 2017;177:G1–G70. doi: 10.1530/EJE-17-0430. - DOI - PubMed
    1. Gravholt C.H., Viuff M., Just J., Sandahl K., Brun S., van der Velden J., Andersen N.H., Skakkebaek A. The changing face of Turner syndrome. Endocr. Rev. 2023;44:33–69. doi: 10.1210/endrev/bnac016. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources